| |
RESULTS OF EXTRAORDINARY GENERAL MEETING -
1 October 2008
Full Release |
| |
Osmetech plc (OMH.L), the international molecular diagnostics business, today announces interim results for the 6 months ended 30 June 2008 -
25 September 2008
Full Release |
| |
Osmetech and QIAGEN sign development and supply agreement for QIAplex-based respiratory viral molecular test -
22 September 2008
Full Release |
| |
SEC Registration Statement F-1 -
12 September 2008
Full Release |
| |
Proposed issue of American Depositary Shares and new Ordinary Shares and proposed listing of American Depositary Shares on NASDAQ Global Market -
12 September 2008
Full Release Full Circular |
| |
Osmetech plc Announces Initial Public Offering of American Depositary Shares -
12 September 2008
Full Release |
| |
Board Changes -
12 August 2008
Full Release |
| |
Osmetech Says FDA Clearance of Its Warfarin
Test Will Help Expand Menu, Installed Base -
22 July 2008
Full Release |
| |
Osmetech announces first shipments of new eSensor® XT-8 platform and Warfarin Sensitivity Test - 30 July 2008
Full Release |
| |
FDA clears Osmetech's Warfarin Sensitivity Test and new eSensor® XT-8 platform - 21 July 2008
Full Release |
| |
Change of Adviser - 21 July 2008
Full Release |
| |
Results of AGM - 14 May 2008
Full Release |
| |
Osmetech plc preliminary results for the 12 months ended 31 December 2007 - 28 March 2008
Full Release |
| |
Osmetech licenses Roche polymerase technology - 12 March 2008
Full Release |
| |
Marshfield Clinic Discovers Gene Variant Which Will Significantly Enhance the Accuracy of Molecular Tests for Warfarin Metabolism - 12 February 2008
Full Release |
| |
Disclosure of Significant Shareholdings - 11 January 2008
Full Release |
| |
Warfarin test submitted for FDA approval - 7 January 2008
Full Release |
| |
Disclosure of significant shareholding -12 December 2007
Full Release |
| |
Disclosure of significant shareholding - 26 November 2007
Full Release |
| |
Disclosure of significant shareholding - 19 November 2007
Full Release |
| |
Disclosure of significant shareholding - 12 November 2007
Full Release |
| |
Commencement of clinical trials for warfarin - 12 November 2007
Full Release |
| |
Osmetech Licenses Warfarin Biomarker from Marshfield Clinic - 2 November 2007
Full Release |
| |
Disclosure of Significant Shareholdings - 8 November 2007
Full Release |
| |
Disclosure of Significant Shareholdings - 7 November 2007
Full Release |
| |
Disclosure of Significant Shareholdings - 22 October 2007
Full Release |
| |
Osmetech To Be Awarded New Electrochemical Detection Patents - 4 October 2007
Full Release |
| |
Disclosure of Significant Shareholdings - 3 October 2007
Full Release |
| |
Disclosure of Significant Shareholdings - 27 September 2007
Full Release |
| |
Interim Results for the 6 months to 30 June 2007 - 27 September 2007
Full Release |
| |
U.S. Food and Drug Administration (“FDA“) update labelling for warfarin - 17 August 2007
Full Release |
| |
Osmetech licenses SAM technology to Minerva Biotechnologies - 18 June 2007
Full Release |
| |
Osmetech licenses Roche Hot Start Polymerase Technology - 5 June 2007
Full Release |
| |
Osmetech plc – AGM Statement - 3 May 2007
Full Release |
| |
Annual Report and Accounts 2006 - 3 April 2007
Full Release |
| |
Preliminary Results for the year ended 31 December 2006 - 20 March 2007
Full Release |
| |
Osmetech plc - Cancellation of Warrants - 20 March 2007
Full Release |
| |
Osmetech licenses VKOR pharmacogenetic marker for warfarin dosage management from University of Washington - 09 March 2007
Full Release |
|
Appointment of Director - 14 February 2007
Full Release |
| |
Completion of US$ 44.9 million sale of Critical Care Division to IDEXX - 01 February 2007
Full Release |
| |
Molecular Diagnostics supply agreement - 16 January 2007
Full Release |
| |
Osmetech and EPIDAUROS establish strategic partnership to develop pharmaceutical companion diagnostics and novel molecular diagnostic products - 09 January 2007
Full Release |
| |
| |
Disposal of Critical Care Division - 18 December 2006
Full Release |
| |
Osmetech increases patent holdings - 15 November 2006
Full Release |
| |
Osmetech licenses pharmacogenetic marker for P450-CYP2D6 from EPIDAUROS - 16 October 2006
Full Release |
| |
Osmetech licenses self-assembling monolayer (SAM) nanotechnology to Evanston, Illinois-based Ohmx Corporation - 10 October 2006
Full Release |
| |
Interim Results for the 6 months to 30 June 2006 - 13 September 2006
Full Release |
| |
Trading Update - 10 July 2006
Full Release |
| |
Trading update and Placing of 71,000,000 new ordinary shares - 16 June 2006
Full Release Full Circular |
| |
AGM Statement - 3 May 2006
Full Release |
| |
Osmetech Annual Report & Accounts for the 8 months ended 31 December 2005 - 3 April 2006
Investors - Company Reports |
| |
Launch of eSensor Cystic Fibrosis Carrier Detection System - 28 March 2006
Full Release |
| |
Preliminary Results for the 8 months to 31st December 2005 - 21 March 2006
Investors - Company Reports |
| |
FDA clearance for cystic fibrosis molecular diagnostics test - 24 January 2006
Full Release |
| |
Appointment of Nominated Advisor and Broker - 20 January 2006
Full Release |
| |
Trading Update - 19 January 2006
Full Release |
| |
| |
Osmetech Annual Report and Accounts for 2005 - 8 September 2005
Investors - Company Reports |
| |
Preliminary Results for the 12 months to 30th April 2005 - 2 September 2005
Full Release |
| |
Osmetech appoints head of newly acquired CMS - 4 August 2005
Full Release |
| |
New OPTI products update - 1 August 2005
Full Release |
| |
CMS Cystic Fibrosis clinical research poster - 14 July 2005
Full Document (pdf) |
| |
Proposed acquisition of Clinical Micro Sensors, Inc. ("CMS") from Motorola, Inc., and Placing - 1 July 2005
Full Release Full Circular |
| |
Vial Technology License to Roche Diagnostics - 27 April 2005
Full Release |
| |
Interim Report for the 6 months to 31st October 2004 - 27 January 2005
Full Release |
| |
|
